Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Salvage Radiotherapy for Prostate Cancer Recurrence
NCT04931979Phase 2Recruiting
- Start
- Oct 2022
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in prostate cancer (PCa). Primary endpoint: Complete biochemical response at 60 weeks. Started Oct 2022; status: recruiting.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04931979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931979.